Purpose Studies comparing two or more vaccine platforms have historically evaluated each platform based on its ability to induce an immune response and may conclude that one vaccine is more eYcacious than the other(s), leading to a recommendation for development of the more eVective vaccine for clinical studies. Alternatively, these studies have documented the advantages of a diversiWed prime and boost regimen due to ampliWcation of the antigen-speciWc T-cell population. We hypothesize here that two vaccine platforms targeting the same antigen might induce shared and distinct antigen-speciWc T-cell populations, and examined the possibility that two distinct vaccines could be used concomitantly. Experimental design Using recombinant poxvirus and yeast vaccines, we compared the T-cell populations induced by these two platforms in terms of serum cytokine response, T-cell gene expression, T-cell receptor phenotype, antigen-speciWc cytokine expression, T-cell avidity, and T-cell antigen-speciWc tumor cell lysis. Results These studies demonstrate for the Wrst time that vaccination with a recombinant poxvirus platform (rV/F-CEA/TRICOM) or a heat-killed yeast vaccine platform (yeast-CEA) elicits T-cell populations with both shared and unique phenotypic and functional characteristics. Furthermore, both the antigen and the vector play a role in the induction of distinct T-cell populations. Conclusions In this study, we demonstrate that concurrent administration of two vaccines targeting the same antigen induces a more diverse T-cell population that leads to enhanced antitumor eYcacy. These studies provide the rationale for future clinical studies investigating concurrent administration of vaccine platforms targeting a single antigen to enhance the antigen-speciWc immune response.
Introduction
Numerous immunotherapy studies have been reported comparing diVerent vaccine platforms that target the same antigen, in terms of their ability to induce immune cell activity and antitumor eVects [1] [2] [3] [4] [5] [6] [7] [8] [9] . Such studies either choose the more eYcacious vaccine for further study, or employ a diversiWed prime and boost strategy to amplify the T-cell response. We have previously reported the immune responses and antitumor eYcacy of the diversiWed prime and boost vaccine regimen of recombinant vaccinia (rV) and recombinant fowlpox (rF) viruses containing murine B7-1, ICAM-1, and LFA-3 transgenes as well as the human carcinoembryonic antigen (CEA) transgene (rV/F-CEA/ TRICOM) in preclinical models [6, [10] [11] [12] [13] [14] . Recently, we reported the immune responses and antitumor eVects of a recombinant Saccharomyces cerevisiae (yeast-CEA) vaccine in preclinical models [15, 16] . The antitumor eVects elicited by either vaccine are mainly attributed to the induction of a CEA-speciWc T-cell population. Here, we describe the Wrst study to our knowledge to concurrently administer two diVerent vaccine platforms targeting the same antigen in an antitumor model. The recombinant vaccinia and fowlpox vectors infect APCs and express transgenes via poxvirus promoters. The yeast vaccine is developed by transfection of Saccharomyces cerevisiae with a recombinant yeast plasmid, which then expresses the recombinant protein (e.g. CEA) internally. The heat-killed yeast when employed as a vaccine is then internalized by DCs at which time the protein is released in the APC and processed. Thus the CEA antigen delivered by either vaccine may be processed and presented diVerently by APCs, possibly leading to the induction of distinct T-cell populations. Previous in vitro studies have also shown that an array of cytokines is released by DCs upon exposure to the yeast vaccine [15] . We hypothesized that due to both vaccine platform-and antigen-speciWc eVects, the rV/F-CEA/TRI-COM and yeast-CEA vaccines would induce distinct T-cell populations, and that concurrent administration of the two vaccines would thus result in a more diverse T-cell population.
This study demonstrates for the Wrst time that both the vaccine platform and the antigen can have a role in the induction of T-cell populations with both shared and unique cytokine responses, gene expression proWles, and T-cell receptor phenotypes. Furthermore, T-cell lines developed from vaccinated CEA-transgenic (CEA-Tg) mice have diVerent avidity and cytolytic activity in vitro. These studies indicate that phenotypically and functionally distinct T-cell populations are induced by two distinct vaccine platforms targeting the same antigen. Because our study found that rV/F-CEA/TRICOM and yeast-CEA induced distinct T-cell populations, we hypothesized that concurrent administration of the vaccines may induce a more diverse T-cell population consisting of T cells generated from both vaccines. Finally, our study showed that the two vaccines may be combinatorially administered to improve antitumor eYcacy. Our study diVers from the typical diversiWed prime-boost studies in the literature. Here, we use two distinct vaccine platforms that when concurrently administered do not inhibit one another, and that induce a more diverse T-cell population upfront that is then boosted and expanded in magnitude with each subsequent vaccination. The concurrent administration of two vaccines targeting a single antigen could be advantageous for the treatment of cancer patients, in which a potent immune response may be created at the earliest stages of treatment. These results provide a rationale for the concurrent administration of two distinct vaccine platforms targeting a single antigen for the induction of a more diverse T-cell population directed against a tumor-associated antigen for the treatment of cancer.
Materials and methods

Mice and tumor cell lines
For in vitro stimulation of lymphocytes, female C57BL/6 (H-2b) mice were obtained from the National Cancer Institute, Frederick Cancer Research and Development Facility (Frederick, MD). A breeding pair of C57BL/6 mice homozygous for expression of the human CEA gene (CEA-Tg) was generously provided by Dr. John Shively (City of Hope, Duarte, CA). Homozygosity for CEA expression was conWrmed by PCR analysis of mouse-tail DNA [13] . Six-to eight-week-old female mice were used for all experiments, and were housed in micro-isolator cages under pathogen-free conditions in accordance with AAALAC guidelines. Experimental studies were carried out under approval of the NIH Intramural Animal Care and Use Committee. The target tumor cell line EL-4 (H-2b, thymoma) was obtained from American Type Culture Collection (Manassas, VA). LL/2 murine lung adenocarcinoma tumor cells were gifted by Dr. Chandan Guha (Albert Einstein College of Medicine, New York, NY). LL/2 murine lung carcinoma cells expressing human CEA (LL2-CEA) were generated by retroviral transduction with CEA cDNA, as previously described [17] . Cells were maintained in complete medium (RPMI or DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin).
Vaccine constructs
Recombinant vaccinia (rV) and recombinant fowlpox (rF) viruses containing murine B7-1, ICAM-1, and LFA-3 genes as well as the human CEA gene (rV/F-CEA/TRI-COM) have been previously described [10, 12] . The murine GM-CSF-expressing rF virus (rF-GM-CSF) has been previously described [18] . A recombinant S. cerevisiae construct expressing the full-length CEA protein (yeast-CEA) has been previously described [15] . Yeast-CEA was produced and heat-killed for these studies as previously described [19] .
Vaccination schedules
For serum cytokine analysis, CEA-Tg mice (n = 2) were vaccinated with 1 £ 10 8 pfu rV-CEA/TRICOM or 4 YU/ animal (1 YU = 10 7 yeast particles) of yeast-CEA as previously described [16] . In all other studies for the rV/F-CEA/ TRICOM vaccine group, CEA-Tg mice were primed with 1 £ 10 8 pfu rV-CEA/TRICOM admixed with 1 £ 10 7 pfu rF-GM-CSF on day 0, and boosted every 7 days with 1 £ 10 8 pfu rF-CEA/TRICOM admixed with 1 £ 10 7 pfu rF-GM-CSF. For the rest of this manuscript, this vaccine will be designated rV/F-CEA/TRICOM. In the yeast-CEA vaccine group, CEA-Tg mice were vaccinated every 7 days with yeast-CEA (4 YU/mouse). Mice receiving the combination of rV/F-CEA/TRICOM and yeast-CEA vaccines were primed with 1 £ 10 8 pfu rV-CEA/TRICOM administered subcutaneously on the dorsal right Xank, and with 4 YU/mouse of yeast-CEA delivered subcutaneously on the inner legs and shoulder blades. The separation of the yeast-CEA dose over multiple sites has previously been described [16] , and has been employed here to separate not only the yeast-CEA vaccine, but also the rV/F-CEA/TRICOM to target multiple draining lymph nodes in the mouse. Mice in the combination group were boosted at 1-week intervals for the remainder of the study with 1 £ 10 8 pfu rF-CEA/TRI-COM and yeast-CEA (4 YU/mouse).
Cytokine expression proWles
For serum cytokine analysis, vaccinated mice (see vaccination schedule above) were bled on days 0, 2, and 4 postvaccination and serum was isolated. Cytokine expression was analyzed using a Th1/Th2 and proinXammatory cytokine panel by Linco Diagnostic Services (St. Charles, MO). To measure cytokines secreted by CD8 + T cells from mice vaccinated with rV/F-CEA/TRICOM or yeast-CEA (n = 5), CD8 + T cells were bulk cultured and restimulated in the presence of CEA-572-579 peptide (GIQNSVSA, designated CEA-572) or CEA-526-533 peptide (EAQNTTYL, designated CEA-526) (10 g/ml) as previously described [16] . Cytokine levels were measured using the mouse InXammatory Cytokine Cytometric Bead Array Kit and the mouse Th1/Th2 Cytokine Cytometric Bead Array kit (BD Biosciences, San Jose, CA) according to the manufacturer's instructions.
T-cell receptor (TCR) proWles RNA was isolated using the RNeasy Mini Kit (Qiagen, Inc., Valencia, CA) according to the manufacturer's instructions. RNA was then used in RT-PCR reactions using the Invitrogen SuperScript ® First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. V and V genes were ampliWed using primers and conditions previously described for 19 V and 24 V genes [20, 21] . PCR products were analyzed using the Agilent 2100 Bioanalyzer and Agilent DNA 1000 Reagent Kit (Agilent Technologies, Santa Clara, CA) by on-chip electrophoresis according to the manufacturer's instructions. Agilent 2100 Expert Software (version B.02.06SI418 [Patch 01]) was used to identify PCR products by size (bp) and quantity (nmol/L). For each sample, quantities of each gene present were summed, and for each gene, a percent of the total TCR V or V repertoire was calculated. cDNA oligoarray CEA-Tg mice were either untreated or vaccinated 3 times at 1-week intervals with rV/F-CEA/TRICOM or yeast-CEA. On day 33, splenocytes were harvested and RNA was isolated. T-and B-cell activation, chemokines and chemokine receptors, and common cytokines cDNA oligoarrays (SABiosciences, Frederick, MD) were used to investigate changes in gene expression. Genes were considered up-regulated or down-regulated if their normalized intensity ratio was ¸2 or ·0.5 (a 2-fold cutoV), respectively, according to manufacturer's recommendations.
CEA-speciWc CTL cell lines and in vitro assays CEA-526-speciWc and CEA-572-speciWc T-cell lines generated from mice vaccinated with rV/F-CEA/TRICOM or yeast-CEA were maintained in culture with CEA-526 or CEA-572 peptide (1 g/ml) and IL-2 (10 U/ml) with fresh irradiated APCs. To measure the ability of the T-cell lines to lyse 111 In-labeled targets, various ratios of T cells were incubated with labeled targets in triplicate at 37°C and 5% CO 2 in 96-well U-bottom plates. In certain studies, anti-MHC class I blocking antibody (H2Db, BD Pharmingen) was used to distinguish between TCR-mediated and NK-like cytotoxicities. Radioactivity in supernatants was measured using a gammacounter (Corba Autogamma, Packard Instruments, Downers Grove, IL). Percentage of tumor lysis was calculated as follows: % tumor lysis = [(experimental cpm -spontaneous cpm)/(maximum cpm -spontaneous cpm)] £ 100. To evaluate the avidity of CEA-speciWc CTL lines, tumor-killing activity was tested as previously described [22] . Data were averaged and graphed as % speciWc lysis. To normalize groups within each experiment, data were also expressed as percentage of maximum lysis versus peptide concentration. Finally, the natural logarithm of the normalized data was plotted against peptide concentration. The avidity of each T-cell population was deWned as the negative log of the peptide concentration that resulted in 50% maximal target lysis [22, 23] and was expressed in nM. The HIV-gag-390-398 peptide (SQVTNPANI, designated HIV-gag peptide) was used as a negative control in this experiment. MHC class I-peptide tetramers speciWc for CEA-526 and CEA-572 were obtained from Beckman Coulter (Fullerton, CA). Where indicated, CTL activity was converted to lytic units (LU), as described by Wunderlich et al. [24] .
Tumor therapy studies
For therapy studies involving LL2-CEA tumors, 6-to 8-week-old female CEA-Tg mice were injected i.v. in the tail with 3 £ 10 5 LL2-CEA cells in a volume of 100 l. Four days post-tumor implantation, mice were primed and then boosted as described above. To enumerate lung metastases, lungs from the mice killed were inXated, stained with India ink, and Wxed in Fekete's solution [25] .
Statistical analysis
GraphPad Prism version 4.0a for Macintosh (GraphPad Software, San Diego, CA) was used to perform statistical analyses on in vivo data. A 2-tailed, nonparametric MannWhitney test was performed for the average number of tumors per mouse at day 45. A log-rank (Mantel-Cox) test was performed for mice bearing >9 pulmonary tumor nodules at day 45 which were deemed to have ·1 week to live. All values were calculated at a 95% conWdence interval and a p value ·0.05 was considered signiWcant.
Results
Vaccine induction of cytokines and chemokines
We Wrst investigated the role of the vaccine in inducing cytokine and chemokine host innate immune responses in vivo that may subsequently inXuence CEA-speciWc T-cell responses. CEA-Tg mice were vaccinated with rV-CEA/ TRICOM or yeast-CEA. Serum was collected and analyzed for a panel of cytokines using a Th1/Th2 and pro-inXammatory cytokine panel. As shown in Fig. 1 , rV-CEA/TRICOM (closed squares) induces a predominantly Th1-type cytokine proWle, where MIP1 , RANTES, GM-CSF, and IL-12p70 levels are high and IL-5 levels are low (Fig. 1a , b, c, and i, respectively). In contrast, yeast-CEA vaccination (open circles) induces a mixed Th1/Th2 cytokine proWle with increased levels of IL-6, IL-1 , and IL1 (Fig. 1d , g, and h, respectively), low levels of MIP1 , RANTES, IL-13, and IL-5 (Fig. 1a, b , f, and i, respectively). These data indicate that vaccination with rV-CEA/TRICOM versus yeast-CEA induces expression of diVerent cytokines, suggesting that diVerent T-cell populations could be induced by each of the vaccine platforms.
Vaccination with rV/F-CEA/TRICOM versus yeast-CEA induces distinct TCR repertoires
We next sought to determine if vaccination with either platform induces CD8 + T-cell populations with distinct TCR repertoires. CEA-Tg mice were vaccinated with either rV/ F-CEA/TRICOM or yeast-CEA as described in the "Materials and methods" section. Untreated mice served as a negative control ( Fig. 2a and d) . Spleens from vaccinated mice were harvested 14 days post-vaccination and pooled. RT-PCR reactions were performed using 19 V -and 24 V -speciWc primers. PCR products were then analyzed and the percentage of the total TCR repertoire was calculated for each gene (Fig. 2) . The TCR V proWles of splenocytes from untreated mice and mice vaccinated with (Fig. 2b and c) . The expression of 12 of the 19 V genes was similar between T cells induced by both vaccines, while 7 V genes (V 5, V 6, V 7, V 8, V 13.1, V 34S-281, and V 5 ) are unique to T-cell populations from one vaccine compared to the other ( Fig. 2b and c) . Comparison of the V repertoires from these same animals indicated that, with a few exceptions, the V proWles also diVer among the two groups of mice ( Table 1 shows that for each array, both rV/F-CEA/TRI-COM and yeast-CEA induce changes in expression of the same genes, including up-regulation of 26 genes by at least 2-fold, the majority of which are involved in cytokine signaling. In addition, both vaccines up-regulated Ltb4r2, a leukotriene receptor involved in chemotaxis of immune cells, genes involved in T-cell proliferation, such as secreted phosphoprotein-1 (Spp1, or osteopontin), and the tumor suppressor Inha. At the same time, each vaccine platform induces unique changes in expression of several genes (Table 1, bold). Yeast-CEA down-regulates genes involved in chemotaxis of immune cells, such as Ccl12, Cxcl9, Ccr9, while rV/F-CEA/TRICOM does not alter the expression of any of these genes. The results from this experiment indicate that the two vaccine platforms induce To determine the antigen-speciWc response of T-cell populations induced by the vaccines, we investigated the cytokines produced by T cells from vaccinated animals after in vitro stimulation with either of two discrete CEA epitopes (CEA-572 and CEA-526) (Fig. 3a) . We also observed that two diVerent CEA epitopes induce diVerent levels of cytokine production from T cells from vaccinated animals. Higher levels of TNF-are secreted in response to CEA-526 after rV/F-CEA/TRICOM vaccination compared to yeast-CEA (Fig. 3b, closed bar) , yet yeast-CEA vaccination produces signiWcantly higher levels of TNF-when T cells are stimulated with CEA-572 peptide (Fig. 3c, open bar) . Also, T cells from yeast-CEA vaccination induce higher levels of IL-2 compared to T cells from rV/F-CEA/TRICOM vaccination, when stimulated with the CEA-526 and CEA-572 peptides ( Fig. 3b and 3c , open bars). Similarly, after vaccination with rV/F-CEA/ TRICOM, T cells induce higher levels of IFN-compared to yeast-CEA vaccination in response to the CEA-526 and CEA-572 peptides (Fig. 3b and c, closed bars) .
The data also show that T cells from vaccinated animals secrete diVerent levels of various cytokines in response to a single CEA epitope. T cells from mice vaccinated with yeast-CEA secrete IL-2, IL-10, TNF-, IFN-, IL-5, and IL-4 in response to the CEA-572 epitope (Fig. 3c, open  bars) ; on the other hand, T cells from mice vaccinated with rV/F-CEA/TRICOM secrete signiWcantly higher levels of IFN-compared to yeast-CEA in response to the CEA-572 peptide and lower levels of IL-10 and TNF-in response to the CEA-572 epitope (Fig. 3c, closed bars) . These results indicate that the T-cell populations induced by vaccination with rV/F-CEA/TRICOM or yeast-CEA are antigen-speciWc and functionally distinct.
T-cell lines developed from mice vaccinated with rV/F-CEA/TRICOM versus yeast-CEA have distinct TCR repertoires and functional avidity
To further explore potential diVerences in the functionality of T cells from mice vaccinated with either rV/F-CEA/TRI-COM or yeast-CEA, T-cell lines speciWc for either CEA-526 or CEA-572 peptide were created from vaccinated CEA-Tg mice as described in the "Materials and methods". V TCR proWles from the 4 cell lines indicate that the T-cell populations have shared and distinct V TCR repertoires. In T cells from vaccinated mice stimulated with the CEA-526 epitope, the T cells have shared expression of Fig. 4a and c) . In T cells from vaccinated mice stimulated with the CEA-572 epitope, the T cells have shared expression of 15 out of the 19 V genes and unique expression of 4 V genes ( Fig. 4b and d) . Similar results were seen when V TCR proWles were analyzed (data not shown). In addition, expression of selected V TCR genes of the T-cell lines were conWrmed by Xow cytometry using commercially available monoclonal antibodies (data not shown). These data provide further evidence that the T-cell populations from mice vaccinated with either rV/F-CEA/ TRICOM or yeast-CEA are both platform-and antigenspeciWc.
To characterize the functional diVerences between T cells from either vaccine, we compared the CEA-speciWc cytolytic activity of T cells generated from rV/F-CEA/TRI-COM or yeast-CEA vaccination. The purity of the T-cell line cultures was conWrmed via cell surface staining with monoclonal antibodies to identify CD8, CD4, and NK cells followed by Xow cytometry (data not shown). In addition, tetramer staining using MHC class I-peptide tetramers speciWc for CEA-526 or CEA-572 conWrmed peptide speciWcity for the T-cell lines (data not shown). Figure 5a and b shows that a CEA-526 peptide-speciWc T-cell line generated from rV/F-CEA/TRICOM has higher lytic activity compared to a T-cell line generated from yeast-CEA vaccination. T-cell lines speciWc for the CEA-572 epitope both demonstrated similar levels of cytolytic activity ( Fig. 5c  and d ). Figure 5b inset shows that the CEA-526-speciWc T-cell line generated from rV/F-CEA/TRICOM vaccination had a 23.3-fold higher avidity than the CEA-526-speciWc T-cell line generated from yeast-CEA vaccination. The CEA-572-speciWc T-cell lines were also used in a CTL assay targeting 111 In-labeled LL2-CEA cells. CEA-572-speciWc T cells from mice vaccinated with either rV/F-CEA/TRICOM or yeast-CEA were cultured for 20 weeks prior to this (Fig. 5f ) had a higher level of activity compared to the T-cell line from mice vaccinated with rV/F-CEA/TRICOM (Fig. 5e) when LL2-CEA cell lysis was normalized to that of LL2 cells. To conWrm that the cell lysis observed in Fig. 5e and f was TCR-mediated and not due to NK cell activity, CTL experiments with blocking monoclonal antibodies speciWc for MHC class I molecules were performed with LL2-CEA tumor targets and normalized to LL2 target cells as a control and showed that the presence of MHC class I blocking antibody abrogated cell lysis. The lack of NK cell-mediated lysis was further conWrmed in a CTL using YAK1 targets which found that the various T-cell lines did not lyse YAK1 target cells. Together, these results indicate that the lytic activity of T-cell lines created from diVerent vectors targeting the same CEA-epitope is TCR-mediated and levels of cell lysis are similar when targeting peptide-pulsed target cells, although their ability to lyse CEA-expressing tumor targets diVers. Additionally, the avidity of rV/F-CEA/TRICOMinduced T-cell lines may be higher than that of T-cell lines created from yeast-CEA vaccination. These results further characterize the T-cell populations from mice vaccinated with rV-CEA/TRICOM or yeast-CEA as platform-speciWc.
Combining rV/F-CEA/TRICOM and yeast-CEA is an eYcacious antitumor therapy in a murine orthotopic pulmonary metastasis model
We next conducted studies to determine if concurrent administration of the two vaccines would generate antitumor activity superior to vaccination with either vaccine platform alone. CEA-Tg mice were injected i.v. with murine lung carcinoma cells expressing CEA (LL2-CEA cells). On day 4, mice were primed with rV-CEA/TRI-COM, or yeast-CEA, or a combination of both vaccines. A group of mice was left untreated as a control. Mice were boosted with rF-CEA/TRICOM, or yeast-CEA, or the combination, respectively, 7 days later and every week until the duration of the experiment. On day 45, mice were killed, lungs were inXated and Wxed as described in "Materials and methods", and the number of metastases per animal was calculated (Fig. 6) . Untreated mice had an average of 10. In-labeled LL2-CEA in an overnight assay at the indicated ratios. Data were normalized to LL2 (negative control) tumor targets. Bars indicate standard error from triplicate wells and yeast-CEA had 2.80 metastases per mouse ( §0.77); this combination group was the only group with a signiWcantly lower number of metastases compared to the untreated control (p = 0.015). Also, the maximum number of metastases per mouse for the untreated, rV/F-CEA/TRI-COM, and yeast-CEA groups was 36, 24, and 18, respectively, while the maximum number of metastases in the combination group was 7. Moreover, the log-rank test (mice bearing >9 pulmonary tumor nodules on day 45; assumed to have ·1 week to live) showed statistical signiWcance in tumor number between untreated mice and the mice that received the combination of rV/F-CEA/TRICOM and yeast-CEA (p = 0.0027). Also, mice treated with rV/F-CEA/TRICOM alone versus concurrent vaccination with rV/F-CEA/TRICOM and yeast-CEA showed statistical signiWcance in tumor number (p = 0.0293). In addition, there was statistical signiWcance between mice treated with yeast-CEA alone versus concurrent vaccination with rV/F-CEA/TRICOM and yeast-CEA (p = 0.0017). These results, taken together, indicate that concurrent administration of rV/F-CEA/TRICOM and yeast-CEA vaccines can increase antitumor eYcacy.
Discussion
We have previously reported that both the rV/F-CEA/TRI-COM and yeast-CEA vaccines induce robust immune responses against CEA in self-antigen CEA-Tg mice [10, 11, 15, 16] . This study was undertaken to focus on the distinct T-cell populations induced by each platform and their combined use. Millar et al. [5] previously showed that the functionality of T-cell populations induced by two diVerent platforms (rV and recombinant adenovirus) targeting the same antigen (OVA) did not diVer. Our study provides evidence that both the vaccine platform and the antigen can aVect the functionality of the T-cell population induced by rV/F-CEA/TRICOM and yeast-CEA vaccines. To investigate the platform-and antigen-speciWc induction of T-cell functionality and phenotype, we compared the T-cell populations induced by both vaccines in terms of cytokine production, gene expression, and TCR proWling. Our studies found that rV-CEA/TRICOM induces a Th1 response and CD8 + T cells with a Tc1 phenotype, while yeast-CEA induces a mixed Th1/Th2 response and CD8 + T cells with a mixed Tc1/Tc2 phenotype (Figs. 1 and 3) . These diVerences in cytokine response could also be due to diVerences in aYnity for peptide (Fig. 5b, inset) , magnitude of the response (Fig. 5e and f) , or timing of activation, which may diVer due to the diVerences in antigen processing and presentation after administration of either vaccine. We observed up-regulation of genes involved in immune cell migration and TCR signaling and T-cell proliferation by both vaccines (Table 1) . Although these vaccines each elicit distinct gene expression proWles for genes involved in cellular pathways important in T-cell activation and chemotaxis of immune cells, both elicit antigen-speciWc immune responses and antitumor eYcacy, presumably through either Th1 or a mixed Th1/Th2 response. We also observed that the T-cell populations induced by either vaccine have both shared and unique V and V TCR gene usage (Fig. 2) and that T-cell lines created from vaccinated CEATg mice, speciWc for one of two CEA epitopes, demonstrate diVerential avidity and antigen-speciWc cytolytic activity (Fig. 5 ). Taken together, these studies demonstrate that the two vaccines induce distinct T-cell populations and the diVerences in the phenotype and function of these T-cell populations may be attributed to both the platform and the antigen. The mode of antigen delivery by either vaccine platform may inXuence the generation of these distinct responses. The mechanism by which yeast-CEA predominantly activates the immune response is through the uptake of the CEA-expressing yeast and subsequent processing and presentation of the CEA antigen by DCs [15] , while the rV/F-CEA/TRICOM vectors infect cells, inducing intracellular expression that allows the CEA antigen to be processed and presented [10] . Another diVerence observed is that rV/F-CEA/TRICOM vaccination induces the production of CEA-speciWc antibody while yeast-CEA does not (data not shown). Such mechanistic diVerences in the activation of the cellular and humoral arms of the immune system may also inXuence the platform-and antigen-speciWc induction of distinct T-cell populations.
Our studies led us to hypothesize that employing the two vaccines concurrently could lead to a more polyclonal T-cell population that would be advantageous in an anticancer setting while several studies have documented that the induction of a more diverse T-cell population is advantageous in mounting an immune response in various models of disease, including cancer [26] [27] [28] [29] [30] [31] [32] [33] . While there are no reports of concurrent use of vaccines that target the same antigen, we have previously documented the advantages of a diversiWed prime-boost vaccination strategy with recombinant vaccinia and fowlpox vectors targeting CEA [34, 35] . This strategy was employed because immune response to the Wrst vaccine has been shown to reduce the eVects of subsequent vaccinations with the same vector [3, 12, 34, 36] . Therefore, diversiWed prime-boost strategies avoid any immune response against the Wrst vaccine platform while expanding the antigen-speciWc T-cell population with each boost with the second vaccine platform. Similar results demonstrating the clear advantages of a diversiWed primeboost strategy have been described in a variety of cancer and other disease models, including HIV and malaria [36] [37] [38] [39] [40] [41] . The enhanced responses observed in these studies have been attributed to ampliWcation of the population of antigen-speciWc T cells. However, as our study found that rV/ F-CEA/TRICOM and yeast-CEA induced distinct T-cell populations, we hypothesized that concurrent administration of the vaccines may induce a more diverse T-cell population consisting of T cells generated from both vaccines, making a diversiWed prime-boost schedule unnecessary. Our study diVers from diversiWed prime-boost studies because we are trying to maximize the immune response beginning with the initial vaccination by inducing a more diverse T-cell population that is then boosted and expanded in magnitude with each subsequent vaccination. Such a strategy would be eYcacious in cancer patients because a more diverse T-cell population would be induced early in their treatment. We therefore investigated the antitumor eVects of combining rV/F-CEA/TRICOM and yeast-CEA delivered concurrently. We found that combining two vaccines targeting the same antigen induces distinct T-cell populations and results in signiWcantly higher antitumor immunity in a murine orthotopic pulmonary metastasis model (Fig. 6) . Given the various shared phenotypic and functional characteristics of the T-cell populations induced by either vaccine alone, a diversiWed prime-boost strategy may still be useful when combining rF/V-CEA/TRICOM and yeast-CEA. Further studies examining the eYcacy of diversiWed prime and boost as well as concurrent vaccination should be performed in this and other tumor models.
This study showed for the Wrst time that two vaccine platforms targeting the same antigen could be concurrently administrated due to their induction of distinct T-cell populations. Furthermore, our data show that concurrent administration of the two vaccines results in signiWcantly increased antitumor eVects, due to the induction of a more diverse T-cell population targeting the same antigen. These Wndings provide a rationale for future studies concurrently combining vaccines to increase antigen-speciWc immunity.
